T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis.

ABSTRACT:

Background

Current guidelines consider T-DM1 the standard 2^nd line therapy for HER2 positive metastatic breast cancer (MBC) patients following trastuzumab (T) + pertuzumab (P) and taxane 1^st line treatment. Despite this, there are no prospective studies supporting this sequence.

Methods

We performed a meta-analysis using real world data to determine the efficacy of T-DM1 after 1^st line TP in HER2 positive MBC patients. We used a random-effect model to find differences in the rate of 1-year progression free survival (PFS) between TP pre-treated population and the EMILIA phase III pivotal trial.

Results

Seven studies were eligible. The meta-analysis showed a combined 1-year PFS risk difference for T-DM1 efficacy after TP in 2^nd

SUBMITTER: Omarini C 

PROVIDER: S-EPMC9172020 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature